term potentiation (LTP) and soluble Ab levels in an Alzheimer's disease mouse model and show that the role of prions in Ab related toxicity is far from 'black and white' suggesting complex interpretations of the data available thus far.
Pathogenic amyloid formation is characteristic of several neurodegenerative disorders including Alzheimer's and Parkinson's disease, transmissible spongiform encephalopathies and others (Aguzzi & O'Connor, 2010) . The prion diseases are propagated via conversion of the cellular prion protein PrP c into an abnormal b-sheet enriched isoform PrP Sc (Aguzzi & O'Connor, 2010) . In Alzheimer's disease (AD), b-and g-secretases cleave the amyloid precursor protein (APP), resulting in the generation of Ab peptides that aggregate in b-sheet enriched Ab fibrils (De Strooper, 2010) and form the characteristic amyloid plaques in the brain of AD patients. Recent insights suggest that small oligomeric assemblies of Ab, in contrast to monomeric and fibrillar species, are toxic for neuronal synapses, but the molecular targets of these assemblies and the mechanism of toxicity remain very controversial topics (Ashe & Zahs, 2010 , see also supplemental data there). The main problem is that oligomeric Ab assemblies are in a dynamic equilibrium with monomeric and fibrillar Ab assemblies, implying that various biophysical parameters determine the relative abundance of different aggregation states. The dynamic nature of this process makes the definition of such toxic assemblies elusive and probably also explains why so many various direct and indirect interactions of Ab peptides with membrane bound and intracellular proteins have been described (Ashe & Zahs, 2010) . One of the most spectacular candidates in the series of candidate receptors for these toxic assemblies is, without doubt, the prion protein (Lauren et al, 2009 ). Indeed, an interaction between Ab and the prion protein suggests a potential common molecular substratum for the neurotoxicity seen in both diseases. Prion protein (PrP) was identified in an unbiased screening for receptors that could bind Ab 42 oligomers prepared according to a particular protocol to yield Ab-derived diffusible ligands (ADDL) (Lambert et al, 1998) . Such ADDLs are neurotoxic, interfere with LTP and are considered a more or less stable form among several toxic species along the Ab aggregation pathway. The interactions between ADDLs and cellular PrP along with other Ab binding molecules that might mediate AD pathogenesis are depicted in Figure 1 . These oligomers failed to impair LTP in mouse hippocampal slices lacking PrP (Lauren et al, 2009 ) and the same authors have recently demonstrated that in an AD transgenic mouse model (APPswe/Psen1DE9) characterized by amyloid plaques formation and learning and memory deficits, deletion of the endogenous PrP gene prevented the development of the functional deficits despite unchanged levels of Ab generation and Ab deposition in their brains (Gimbel et al, 2010) . The temptation to extrapolate these interesting findings towards real AD is obvious but it requires some caution as other researchers (Balducci et al, 2010) The story is however far from finished. All groups involved agree that PrP has a remarkable good affinity for Ab peptides tested in various conformations (Balducci et al, 2010; Calella et al, 2010; Lauren et al, 2009) . Callela et al investigated the effects of expressing a soluble form of PrP (without its GPI-anchor) in their AD mouse model. In this case, whereas the levels of soluble and insoluble Ab remain unchanged, LTP is less affected. Although seemingly contradictory with Lauren et al, the finding suggests that secreted PrP might interfere with Ab mediated toxic pathways by directly binding to the peptide, not unlike the effect of Ab antibodies in similar experiments. Whether such a protective effect is also observed with endogenously expressed (soluble) PrP remains obviously unaddressed.
» Other aspects of PrP and APP biology also suggest that the situation might be more complicated. « Other aspects of PrP and APP biology also suggest that the situation might be more complicated. Parkin et al, 2007 showed for instance that cellular PrP can inhibit b-secretase-mediated cleavage of APP. The prediction that the lack of functional PrP c would lead to a rise in Ab levels was confirmed by analysing the brain of PrP knock out mice (Parkin et al, 2007) . However, the PrP gene is located close to a quantitative trait locus (QTL) for Ab levels (Ryman et al, 2008) hippocampal neurons (50% compared to wild type). Furthermore, as discussed above, the in vivo generated Ab oligomer pool is likely more complex than any in vitro generated Ab oligomer mixture, and may therefore contain several 'strains' of toxic and less toxic conformers, somewhat resembling PrP Sc (Aguzzi, 2008) .
Each of these conformations might act via different pathways. Therefore, and in conclusion, one cannot exclude that a remarkably high affinity of PrP to Ab could be ascribed to a sub-pool of amyloid species, which is not necessarily the (most) toxic one.
